# Effect of a dietary fiber and magnesium supplement on endothelial dysfunction, inflammation and glycemic control markers in patients with type 2 diabetes mellitus. Randomized, double-blind clinical trial.

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
01/05/2006	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
30/06/2006	Completed	Results
Last Edited	Condition category	<ul><li>Individual participant data</li></ul>
30/06/2006	Nutritional, Metabolic, Endocrine	<ul><li>Record updated in last year</li></ul>

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Susana Castanon

#### Contact details

Ave Cuauhutemoc 330 Colonia Doctores Mexico Distrito Federal Mexico 06720 +52 55627690 ext.21507 or 21481 susanacast@usa.net

# Additional identifiers

EudraCT/CTIS number

IRAS number

#### ClinicalTrials.gov number

#### Secondary identifying numbers

2005-785-022

# Study information

#### Scientific Title

#### Study objectives

Biomarkers of endothelial dysfunction (selectin 2, vascular cell adhesion molecules [vcam], and intercellular adhesion molecule [icam]) will be lower in the patients with dietary fiber and magnesium supplements than those without them.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

The name of the ethical committee that gave approval for the trial is Ethics Subcommittee of the National Commission for Scientific Research, Institute of Mexican Social Security (Comisión Nacional de Investigación Científica, Subcomité de Ética, Instituto Mexicano del Seguro Social), 14/04/2005; reference number: 09-B5-61-2800/983 2005-785-022

#### Study design

Randomized, double-blind, clinical trial

#### Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Not specified

# Study type(s)

Treatment

#### Participant information sheet

# Health condition(s) or problem(s) studied

Diabetes mellitus type 2

#### **Interventions**

There are four arms of treatment. All four groups received the best therapy available to control dm2 which include the ADA nutrition treatment guidelines. There was a nutritionist that gave specific suggestions according to each patient's needs, with an indication of losing weight if necessary. All patients received oral hypoglycaemic products and antihypertensive therapy as much as was needed to achieve the target levels of glucose and blood pressure. Patients were

randomised to receive one of the following interventions:

- 1. Active cookies and active tablets
- 2. Combination of placebo and active cookies
- 3. Combination of placebo and active tablets
- 4. Control group: placebo cookies and placebo tablets

#### **Intervention Type**

Other

#### Phase

**Not Specified** 

#### Primary outcome measure

Biomarkers of endothelial dysfunction (selectin 2, vascular cell adhesion molecules [vcam]) and intercellular adhesion molecule [icam])

#### Secondary outcome measures

- 1. Serum levels of inflammation markers (interleukin-6, C-reactive protein)
- 2. Plasma levels of glycemic control markers (glycated hemoglobin and glucose)

#### Overall study start date

28/11/2005

#### Completion date

30/11/2006

# **Eligibility**

#### Key inclusion criteria

- 1. Having diabetes mellitus type 2 (dm2) according to the American Diabetes Association (ADA) criteria
- 2. Male or female
- 3. Up to 48 months of dm2 diagnosis
- 4. Aged 30-70 years

#### Participant type(s)

Patient

#### Age group

Adult

#### Sex

Both

#### Target number of participants

400

#### Key exclusion criteria

- 1. Clinical evidence of chronic complications at the time of enrolment
- 2. Chronic diarrhea
- 3. Renal function impairment

# Date of first enrolment

28/11/2005

#### Date of final enrolment

30/11/2006

# Locations

#### Countries of recruitment

Mexico

# Study participating centre

Ave Cuauhutemoc 330

Mexico Distrito Federal Mexico 06720

# Sponsor information

#### Organisation

Mexican Institute of Social Security (Instituto Mexicano del Seguro Social) (Mexico)

#### Sponsor details

Ave Cuauhutemoc 330 Colonia Doctores Mexico Distrito Federal Mexico 06720 +55 56276900 ext 21963 mdelpradom@cis.gob

#### Sponsor type

Government

#### Website

http://www.cis.gob.mx

#### **ROR**

https://ror.org/03xddgg98

# Funder(s)

## Funder type

Government

#### **Funder Name**

Mexican Institute of Social Security (Instituto Mexicano del Seguro Social)

#### **Funder Name**

Fabrica de Galletas la Moderna

#### **Funder Name**

Laboratorio Silanes

# **Results and Publications**

### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration